NAD+ vs Orforglipron
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
NAD+GLP-1 / Weight Loss Agonists
Orforglipron- Summary
- NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Half-Life
- Varies by route; IV provides direct cellular delivery
- ~12 hours (once-daily oral dosing)
- Admin Route
- IV, SubQ, Oral
- Oral
- Research
- —
- —
- Typical Dose
- 500–1000 mg
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- Daily for 4–10 days (loading), then monthly maintenance
- Once daily
- Key Benefits
- Restored cellular energy production (ATP)
- Sirtuin activation for longevity and metabolic regulation
- Enhanced DNA repair capacity
- Improved mitochondrial function and biogenesis
- Cognitive clarity and mental energy
- Reduced inflammation
- Addiction withdrawal support (opioids, alcohol, benzodiazepines)
- Improved sleep quality
- Enhanced athletic endurance
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Side Effects
- Flushing and warmth during IV infusion
- Nausea during rapid IV administration
- Chest tightness (from rapid infusion — slow the rate)
- Injection site irritation (subcutaneous)
- +1 more
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Stacks With
- —
- —